Sulforaphane Prevents Hepatic Insulin Resistance by Blocking Serine Palmitoyltransferase 3-Mediated Ceramide...

Area of Science:

• Biochemistry
• Metabolic Diseases
• Nutritional Science

Background:

• Insulin resistance is a key factor in metabolic disorders.
• The molecular mechanisms underlying sulforaphane's (SFA) effects on insulin resistance are not fully understood.
• Ceramide metabolism plays a role in insulin resistance.

Purpose of the Study:

• To investigate whether SFA can improve insulin sensitivity and glucose homeostasis.
• To elucidate the role of ceramide production in SFA's mechanism of action.
• To examine SFA's effects on the insulin signaling pathway and ceramide biosynthesis.

Main Methods:

• In vitro studies using insulin-resistant HepG2 cells to assess glucose metabolism and protein expression.
• In vivo studies in animal models to evaluate glucose tolerance, insulin sensitivity, and hepatic parameters.
• Analysis of ceramide levels, ceramide-related gene transcription, and key protein expression (IRS-1/Akt pathway).
• Gene knockdown of serine palmitoyltransferase 3 (SPTLC3) to confirm its role.

Main Results:

• SFA dose-dependently enhanced glucose uptake and glycogen content in HepG2 cells via the IRS-1/Akt pathway.
• SFA reduced ceramide levels and downregulated ceramide-related gene expression.
• SPTLC3 knockdown prevented ceramide accumulation and alleviated insulin resistance in HepG2 cells.
• In vivo, SFA improved glucose tolerance and insulin sensitivity, reduced SPTLC3 expression, hepatic ceramide, and hepatic triglyceride content.

Conclusions:

• SFA ameliorates hepatic insulin resistance by inhibiting ceramide biosynthesis through modulation of SPTLC3.
• SFA effectively restores glucose homeostasis and improves insulin sensitivity.
• SFA represents a potential therapeutic candidate for managing hepatic insulin resistance via a ceramide-dependent mechanism.